Mode
Text Size
Log in / Sign up
Phase 3 Completed N=304 Randomized Quadruple-blind Diagnostic

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

Lesion in Body Region
Source: ClinicalTrials.gov NCT03986138 ↗
Enrolled (actual)
304
Serious AEs
0.5%
Results posted
Oct 2025
Primary outcomePrimary: Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI — 3.79; 2.26; 3.48; 3.01 mean of a score (on a scale) per patient — p=< 0.0001
◆ Published Evidence
Established
63citations · ~21 / year
Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Radiology · 2023 · Open access · High-confidence link

Summary

The trial aimed at evaluating the efficacy and the safety of gadopiclenol for body Magnetic resonance Imaging (MRI)

Linked Publications

  • Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
    Radiology · 2023 · 63 citations · Open access · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI
3.79; 2.26; 3.48; 3.01; 3.49; 1.78 < 0.0001 sig
SECONDARY
Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Gadobutrol-enhanced MRI
3.82; 3.81; 3.56; 3.53; 3.53; 3.57 <0.0001 sig

Eligibility Criteria

Inclusion Criteria

  • Patient presenting with known or suspected enhancing abnormality(ies) and/or lesion(s) in at least one body region based on a previous imaging procedure performed within 12 months prior to ICF signature. US patients are restricted to the breast in compliance with local approved indications of gadobutrol.

Exclusion Criteria

  • Patient presenting with acute or chronic renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent administration.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03986138) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search